Philippines - English - FDA (Food And Drug Administration)

n/a; importer: taiho pharma asia pacific pte. ltd. philippine branch; distributor: globo asiatico enterprises, inc. - trifluridine , tipiracil (as hydrochloride) - film-coated tablet - 20 mg/8.19 mg

Philippines - English - FDA (Food And Drug Administration)

n/a; importer: taiho pharma asia pacific pte. ltd. philippine branch; distributor: globo asiatico enterprises, inc. - trifluridine , tipiracil (as hydrochloride) - film-coated tablet - 15 mg/6.14 mg

Philippines - English - FDA (Food And Drug Administration)

n/a; importer: agb pharmaceutical trading and consultancy corporation; distributor: globo asiatico enterprises, inc. - cisplatin - solution for injection (iv) - 1 mg/ml (50 mg/50ml)

Philippines - English - FDA (Food And Drug Administration)

medinova pharmaceutical inc; distributor: globo asiatico enterprises, inc. - capecitabine - film-coated tablet - 500mg

United States - English - NLM (National Library of Medicine)

alk-abello, inc. - house dust (unii: eyo007vx98) (house dust - unii:eyo007vx98) - house dust 10000 [pnu] in 1 ml - these products are for diagnostic use only. diagnostic allergenic extracts are indicated for use in skin testing to establish the clinical relevance of specific allergens to which the patient has been exposed. by measuring skin test response, the physician may assess the degree of sensitivity that patients have to the allergens. for extracts standardized in au and bau, see individual directions for use. allergenic extracts for diagnostic use only of coffee, mosquito, cottonseed, and flaxseed have not been shown by adequate data to be safe and effective for therapeutic use. patients on beta blockers can be non-responsive to beta agonists that may be required to reverse a systemic reaction (also, see boxed warning statement and adverse reactions ). the physician should carefully weigh the benefit derived from skin testing vs. the risk to the patient should a systemic reaction arise. patients with unstable asthma or steroid dependent asthmatics and patients with underlying cardiovascular disease are at greater

United States - English - NLM (National Library of Medicine)

alk-abello, inc. - solidago canadensis pollen (unii: 644cz16ir5) (solidago canadensis pollen - unii:644cz16ir5) - equus caballus skin 20000 [pnu] in 1 ml - hyposensitization (injection) therapy is a treatment for patients exhibiting allergic reactions to seasonal pollens, dust, molds, animal danders, various other inhalants, and in situations where the offending allergen cannot be avoided. prior to initiation of therapy, the clinical sensitivity should be established by careful evaluation of the patient’s history confirmed by diagnostic skin testing. hyposensitization should not be prescribed for sensitivities to allergens which can easily be avoided. a patient should not be immunized with preparations of allergens to which the patient has not demonstrated symptoms, ige antibodies, positive skin tests, or properly controlled challenge testing. in most cases, immunotherapy is not indicated for those allergens that can be eliminated or minimized by environmental control. patients on beta-blockers are not candidates for immunotherapy, as they can be non-responsive to beta-agonists that may be required to reverse a systemic reaction (also see warnings and adverse

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - agalsidase beta, quantity: 5.5 mg - injection, powder for - excipient ingredients: nitrogen; monobasic sodium phosphate monohydrate; mannitol; dibasic sodium phosphate heptahydrate - fabrazyme is indicated for the long-term enzyme replacement therapy in patients with a confirmed diagnosis of fabry disease (alpha-galactosidase deficiency).

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - agalsidase beta, quantity: 35 mg - injection, powder for - excipient ingredients: monobasic sodium phosphate; nitrogen; dibasic sodium phosphate heptahydrate; mannitol - fabrazyme is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of fabry disease (alpha-galactosidase deficiency).

Israel - English - Ministry of Health

takeda israel ltd - agalsidase alfa - concentrate for solution for infusion - agalsidase alfa 1 mg/ml - agalsidase alfa - agalsidase alfa - replagal is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of fabry disease (alfa-galactosidase a deficiency).

Australia - English - Department of Health (Therapeutic Goods Administration)

amicus therapeutics pty ltd - migalastat hydrochloride, quantity: 150 mg - capsule, hard - excipient ingredients: magnesium stearate; pregelatinised maize starch; indigo carmine; titanium dioxide; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; gelatin; sodium lauryl sulfate - galafold is indicated for long-term treatment of adult and adolescent patients 12 years and older with a confirmed diagnosis of fabry disease (alpha-galactosidase a deficiency) and who have an amenable mutation (see the table in section 5.1 pharmacodynamic properties, mechanism of action).